This is a routine passive dilution filing with no activist escalation. Yao's stake remains large but static. Monitor for any future 13D amendments that signal a change in strategy or demands, especially if the company pursues a post-investment transaction as noted in the 10-K.
Price Chart
Executive Summary
Yun Yao filed Amendment No. 3 to her Schedule 13D, reporting a decrease in her beneficial ownership percentage from a prior level to 27.34% of Indaptus Therapeutics common stock. The decrease resulted solely from the issuance of 20,338,974 new shares in a private placement on October 16, 2026, not from any sale by Yao. She continues to hold 41,991,000 shares acquired via conversion of Series AA and Series AAA Preferred Stock in March 2026. No change in purpose or demands was disclosed.
Key Financial Metrics
Key Facts
- Yun Yao beneficially owns 41,991,000 shares of Indaptus common stock, unchanged from prior filing.
- Ownership percentage decreased to 27.34% due solely to the issuance of 20,338,974 new shares in an October 16, 2026 private placement.
- Yao's shares were acquired via conversion of Series AA and Series AAA Preferred Stock under a March 19, 2026 Purchase Agreement for $4,317,206.43.
- No shares were bought or sold by Yao in the past 60 days.
- No new demands, strategic review, or changes in purpose were stated in this amendment.
Financial Impact
Passive dilution of Yao's stake from approximately 31.5% to 27.34% due to 20.3M new shares issued in a private placement. No direct financial impact on Yao's holdings.
Risk Factors
- Further dilution from additional equity raises could reduce Yao's influence.
- No stated activist demands — potential for future activism if the company underperforms.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001829126-26-011443 |
| Document: 0001829126-26-011443-index.html | 0001829126-26-011443 |
| Document: 0001829126-26-011443.txt | 0001829126-26-011443 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.46 (+9.65%) |
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.46 (+9.65%) |
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.46 (+9.65%) |
Oct 21, 2026 5d ago | SC 13D/A | $2.99 | awaiting T+60 | — | $3.46 (+15.89%) |
Oct 20, 2026 6d ago | 8-K | $3.16 | awaiting T+60 | — | $3.46 (−9.65%) |
Sep 30, 2026 27d ago | 8-K | $2.30 | awaiting T+60 | — | $3.46 (+50.65%) |
Sep 9, 2026 6w ago | 8-K | $2.56 | awaiting T+60 | — | $3.46 (−35.35%) |
Sep 4, 2026 7w ago | 424B5 | $1.85 | awaiting T+60 | — | $3.46 (−87.30%) |
Sep 1, 2026 8w ago | 8-K | $1.13 | awaiting T+60 | — | $3.46 (−206.64%) |
Aug 26, 2026 8w ago | EFFECT | $1.14 | awaiting T+60 | — | $3.46 (−203.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers